Citable filing context
CRL's research view summarizes recent SEC filing context, starting with earnings from Aug 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 5, 2026 | earnings | Charles River Laboratories reported Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02. |
| May 11, 2026 | other | Shareholders elected directors and approved the 2026 Long-Term Incentive Plan at the annual meeting. |
| May 7, 2026 | earnings | Charles River Laboratories reported Q1 2026 revenue of $995.8 million and non-GAAP EPS of $2.06. |
| Aug 5, 2026 | Guidance: non_gaap_eps | 11.15 to 11.45 |
| Aug 5, 2026 | Guidance: revenue_growth_organic | 0.00 to 1.00 |
| May 7, 2026 | Guidance: non_gaap_eps | 10.80 to 11.30 |
| Aug 5, 2026 | mda_quarterly | Charles River Laboratories (CRL) is navigating a cautious demand environment, particularly within its Discovery and Safety Assessment (DSA) segment, where clients remain conservative despite a slight increase in backlog to $2.0 billion. To improve margins, the company is executing a $300 million annualized cost-savings program focused on workforce right-sizing, site consolidation, and global business services. Financial performance for the first half of 2026 reflects significant portfolio restructuring. Revenue declined slightly to $1.999 billion, pressured by the divestitures of the CDMO, Cell Solutions, and European Discovery Services businesses. While these sales resulted in substantial one-time charges—most notably a $181.7 million loss on the CDMO and Cell Solutions divestiture—they are intended to optimize the company’s long-term capital deployment. Operating income benefited from these actions, alongside a $38.5 million gain from a sale-leaseback transaction in Wilmington, Massachusetts. Strategic capital allocation remains focused on vertical integration, highlighted by the $507.3 million acquisition of a Cambodian non-human primate (NHP) supplier to secure supply chain stability. Liquidity remains sufficient, supported by a $2.0 billion revolving credit facility. The company continues to prioritize shareholder returns, repurchasing $300 million in common stock during the first half of 2026 under a $1 billion authorization. |
| May 7, 2026 | mda_quarterly | Charles River Laboratories is navigating a cautious spending environment, particularly within its Discovery and Safety Assessment (DSA) segment, where the backlog remains steady at $1.9 billion. To improve margins, the company is executing cost-saving initiatives targeting $300 million in cumulative annualized savings by the end of 2026 through workforce right-sizing and site optimization. First-quarter 2026 revenue increased 1.2% to $995.8 million, with growth in Microbial Solutions offsetting declines in Research Models and Services (RMS) large and small model product revenue. Despite an increase in operating income to $119.9 million—bolstered by a $38.5 million gain from a Wilmington asset sale-leaseback—the company reported a net loss of $14.8 million, primarily due to a $118 million pre-tax loss from the divestiture of its CDMO and Cell Solutions businesses. Strategic portfolio adjustments include the $507.3 million acquisition of a Cambodian non-human primate supplier and the $60 million acquisition of PathoQuest. Additionally, the company agreed to sell its European Discovery Services to IQVIA for $145 million. Liquidity is supported by a $2 billion credit facility, with $1.165 billion currently outstanding, and $800 million remaining in its $1 billion stock repurchase program. |
Source: SEC EDGAR filing text and events; period Aug 5, 2026; filed Aug 5, 2026.
CRL company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.